The deal, which builds on LevelBlue’s recent acquisition of Trustwave and Aon, aims to provide customers with a broad portfolio of extended detection and response (XDR), managed detection and response (MDR), and forensic services.
‘Mysterious Elephant’ Moves Beyond Recycled Malware
The cyber-espionage group has been using sophisticated custom tools to target government and diplomatic entities in South Asia since early 2025.
F5 BIG-IP Environment Breached by Nation-State Actor
F5 disclosed a breach this week that included zero-day bugs, source code, and some customer information.
Former FDA leaders take helm of new consultancy, discuss the state of the agency
The FDA’s former chief medical officer Hilary Marston left the agency in June and has already teamed up with Michael Rogers, one of the FDA’s former top inspectors, to be principals of a new consultancy …
BioNTech to get up to €95M in EU funding for a mRNA vaccine site in Africa
Two EU bodies will fund BioNTech with up to €95 million ($110 million) to help build its mRNA vaccine factory in Kigali, Rwanda, which is designed to locally supply vaccines to Africa. The Mainz, Germany …
Novo builds pipeline again with $2.1bn Omeros deal
Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders.
Harvard University Breached in Oracle Zero-Day Attack
The Clop ransomware group claimed responsibility for stealing the university’s data as part of a broader campaign against Oracle customers.
Lilly’s oral GLP-1 racks up two more clinical wins in diabetes
Eli Lilly’s GLP-1 pill has succeeded in two more late-stage trials in type 2 diabetes. The company said Wednesday that orforglipron beat AstraZeneca’s Farxiga at lowering patients’ blood sugar levels in …
Boehringer makes an ADC deal with AimedBio; EyePoint’s $150M stock sale
Plus, news about Scynexis, Step Pharma, Eradivir, J&J, Omnix Medical and Mission Therapeutics: 💼 Boehringer Ingelheim does another cancer deal: The German drugmaker will pay up to $991 million to Seoul …
Novo Nordisk buys kidney, blood disorder drug from Omeros
Novo Nordisk is paying up to $2.1 billion for a mid-stage blood and kidney disorder drug just weeks after saying it would focus its pipeline on obesity and diabetes under a new CEO. The Danish …
UK’s VR-powered medicine maker scheme delivers first results
A UK initiative to train a new generation of workers in medicines manufacturing has been taken up by around 1,200 people since it started last year.
Multidisciplinary perspectives on personalised prevention in youth mental health
The pervasive impact of mental illnesses extends beyond individual suffering, affecting families, communities, and societies at large. Prevention efforts are imperative to mitigate this burden, promoting well-being and resilience across diverse populations. A particularly vulnerable period is adolescence, which is associated with numerous mental health issues that are exacerbated by declining healthy behaviours as well […]